Trials of genetic heart failure drug halted after patient deaths
Alnylam Pharmaceuticals has discontinued development of an experimental therapy for a rare genetic condition that can cause heart failure because of higher death rates in patients taking the drug in late stage trials.
Revusiran, an investigational RNA interference (RNAi) therapeutic, was being…